Disitamab Vedotin, Tislelizumab, and S-1 as First-Line Treatment for Advanced Gastric Cancer

First-line disitamab vedotin plus tislelizumab and S-1 in HER2-overexpressing advanced gastric or gastro-oesophageal junction adenocarcinoma achieved an objective response rate of 89.5% (95% CI 78.5-96.0), but at a cost in toxicity: grade 3 or worse treatment-related adverse events occurred in 64.9% of patients. In this single-arm phase 2 trial (n=57, median follow-up 28.2 months), median progression-free survival was 13.8 months (95% CI 10.3-24.0) and median overall survival was 31.9 months (95% CI 22.1-not reached). Toxicity was mainly haematological and peripheral neuropathy. The trial had no control group, and the authors themselves state that the result requires confirmation in randomised trials.